Research from Water Tower Research, Water Tower Research

Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Research from Water Tower Research

Equity Research Firm

Equity Bottom-Up

<ul><li>GH Research (NASDAQ:GHRS) releases GH001 final Phase 2b OLE data.</li><li>The final data from GH Research’s six-month open-label extension (OLE) study of its lead fast-onset and short-acting 5-MeO-DMT monotherapy candidate GH001 in treating treatment-resistant depression (TRD) has been released with a headline remission rate of 73% at six months.</li><li>The results did not disclose the changes in MADRS from baseline, but in any event the remission data appears to represent a good outcome. But let’s examine the results further.</li></ul>

GH Research (NASDAQ:GHRS) releases GH001 final Phase 2b OLE data.The final data from GH Research’s six-month open-label extension (OLE) study of its lead fast-onset and short-acting 5-MeO-DMT monotherapy candidate GH001 in treating treatment-resistant depression (TRD) has been released with a headline remission rate of 73% at six months.The results did not disclose the changes in MADRS from baseline, but in any event the remission data appears to represent a good outcome. But let’s examine the results further.

Cybin, Inc: CYB003 Vs. GH001 - Duration, Durability and Protocol Execution